Clinical trial
Efficacy, Safety and Tolerability of Denosumab in the Treatment of Rheumatoid…
NCT00095498 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00095498 |
|---|---|
| Title | Efficacy, Safety and Tolerability of Denosumab in the Treatment of Rheumatoid Arthritis |
| Official title | A Randomized, Double-blind, Placebo-controlled, Multi-dose Phase 2 Study to Determine the Efficacy, Safety and Tolerability of Denosumab in the Treatment of Rheumatoid Arthritis |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Drug |
| Interventions | placebo, denosumab |
| Enrollment | 227 |
| Start date | Aug 11, 2004 |
| Primary completion | Apr 1, 2007 |
| Completion | Apr 1, 2007 |
| First posted | Nov 8, 2004 |
| Last update posted | Oct 25, 2021 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: